Reference is made to the stock exchange announcement published by Lifecare ASA
(the "Company") on 7 January 2026 regarding the commencement of the
subscription period in the partially underwritten rights issue (the "Rights
Issue").
Subscription rights were allocated to existing shareholders as of 2 January
2026 (as registered in the VPS as of 6 January 2026). Each subscription right
entitles the holder to subscribe for and be allocated one (1) new share at the
subscription price in the Rights Issue of NOK 0.50 per share.
Subscribers in the Rights Issue will, without cost, receive warrants in two
series: (a) three (3) warrants for every four (4) new shares allocated to, and
paid by, them in the Rights Issue, which will be exercisable in the exercise
period from 2 March 2026 to 13 March 2026 ("Warrants Series 1"); and (b) three
(3) warrants for every four (4) new shares allocated to, and paid by them, in
the Rights Issue, which will be exercisable in the exercise period from 1 June
2026 to 12 June 2026 ("Warrants Series 2" and together with Warrants Series 1,
the "Warrants"). By subscribing for new shares in the Rights Issue,
subscribers will at the same time subscribe for the corresponding number of
Warrants.
Hannibal Invest AS, a company closely associated with Hans Hekland, board
member of the Company, has subscribed for 200,000 new shares in the Rights
Issue, of which 187,739 new shares have been subscribed through the exercise
of subscription rights, and will as such be allocated to Hannibal Invest AS in
accordance with the terms of the Rights Issue. The remaining 12,261 new shares
subscribed constitute over-subscription, and there can be no assurance that
new shares (or the corresponding number of Warrants as set out below) will be
allocated for such over-subscription.
Further, in accordance with the terms of the Rights Issue, Hannibal Invest AS
has at the same time subscribed for in total 300,000 Warrants, of which 18,391
Warrants relate to over-subscription.
Please see the attached PDMR form for further details.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-01-14 14:05 CET.